Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q) ; volume:10 ; number:1 ; day:26 ; month:6 ; year:2017 ; pages:1-8 ; date:12.2017
Journal of hematology & oncology ; 10, Heft 1 (26.6.2017), 1-8, 12.2017
- Keyword
-
Krebs
Onkologie
- Creator
- Contributor
-
Giagounidis, Aristoteles
Selleslag, Dominik
Beyne-Rauzy, Odile
Mittelman, Moshe
Muus, Petra
Nimer, Stephen D.
Hellström-Lindberg, Eva
Powell, Bayard L.
Guerci-Bresler, Agnes
Sekeres, Mikkael A.
Deeg, H. Joachim
Del Cañizo, Consuelo
Greenberg, Peter L.
Shammo, Jamile M.
Skikne, Barry
Yu, Xujie
List, Alan F.
SpringerLink (Online service)
- DOI
-
10.1186/s13045-017-0491-2
- URN
-
urn:nbn:de:1111-201709212877
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fenaux, Pierre
- Giagounidis, Aristoteles
- Selleslag, Dominik
- Beyne-Rauzy, Odile
- Mittelman, Moshe
- Muus, Petra
- Nimer, Stephen D.
- Hellström-Lindberg, Eva
- Powell, Bayard L.
- Guerci-Bresler, Agnes
- Sekeres, Mikkael A.
- Deeg, H. Joachim
- Del Cañizo, Consuelo
- Greenberg, Peter L.
- Shammo, Jamile M.
- Skikne, Barry
- Yu, Xujie
- List, Alan F.
- SpringerLink (Online service)
Other Objects (12)
Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q) : A Case Series
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Niedrigrisiko-MDS mit Deletion 5q : aktueller Stand zu Prognose und Behandlungsstrategien eines komplexen Krankheitsbilds
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
Sieg Sonderkarte 5q
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q) : A Case Series
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Niedrigrisiko-MDS mit Deletion 5q : aktueller Stand zu Prognose und Behandlungsstrategien eines komplexen Krankheitsbilds
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
Sieg Sonderkarte 5q
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses
Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q) : A Case Series
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
Niedrigrisiko-MDS mit Deletion 5q : aktueller Stand zu Prognose und Behandlungsstrategien eines komplexen Krankheitsbilds
Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
Sieg Sonderkarte 5q